tbuckley/cabot-search huggingface dataset:
Immunotherapy in Hay Fever with Two Major Allergens 19, 25 and Partially Purified Extract of Timothy Grass Pollen
Authors: O. ØSterballe, H. Løwenstein, P. Prahl, P. Skov, B. Weeke
Journal: Allergy (1981)

Grass pollen hay fever patients were hyposensitized in a prospective 3‐year double blind study with two timothy extracts. Group WPA (20 patients) was treated with partially purified extract = whole pollen allergens (WPA) (Alutard®SQ) and group PPA (20 patients) was treated with a purified pollen allergen (PPA) = two isolated major allergens, Ag19 and Ag25. Both aluminiumhydroxide adsorbed extracts were biologically standardized. Clinical results from the first season have been recently published and WPA showed significantly fewer symptoms ( P = 0.001) than PPA. Corresponding preseasonal and seasonal in vitro results are presented here. Serum total IgE, specific IgE versus total and individual allergens of timothy pollen and allergen‐specific IgG showed a rapid increase in both groups until the season but showed no further increase or decrease during the season. Specific IgE was shown to correlate to specific IgG during hyposensitization. Group WPA, with fewer symptoms in grass pollen season than group PPA showed a significantly higher increase of specific IgG and IgE than group PPA, but individual symptom scores were not correlated to specific IgG or IgE, or their ratio. Specific IgE and IgG increases were not correlated to dosage. Surprisingly, almost all females were low‐responders to specific IgG and IgE though they had equal symptom scores, dosage, and side effects as males, while the characteristics of high‐responders to antibody were: youngest individuals and shortest duration of symptoms prior to treatment. Crossed radioimmunoelectrophoresis (CRIE) showed specific reaction to stimuli but no development of allergy against new timothy antigens. High response of IgE to Ag 19 in CRIE during initial hyposensitization seems suitable as marker for prospective evaluation of clinical effect in grass pollen hyposensitization. Nasal secretion was collected after methacholine provocation, and total IgE and specific IgE detected. There was no response to treatment, only a slight increase during the season. No decrease in nasal reactivity to methacholine was noted during one preseasonal hyposensitization.
ALLERGY IN THE AGED
Authors: R A KERN
Journal: Annals of Internal Medicine (1951)

Article1 August 1951ALLERGY IN THE AGEDRICHARD A. KERN, M.D., F.A.C.P.RICHARD A. KERN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-35-2-315 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis discussion of allergy in the aged is justified by a number of reasons. There are differences in the incidence of the various kinds of allergic diseases and at times also differences in the clinical pictures of the same disease in the old as compared with younger patients. Chronicity is a major characteristic of allergic disorders in the elderly. There are significant differences in etiologic factors and in non-allergic complications encountered in the aged with allergic conditions. It is harder to find in advanced years the specific causes of allergic disease because of the diminished or lost reactivity of the...Bibliography1. Dublin LI: Statistical and social implications in the problem of our aging population, University of Pennsylvania Press, Publications of Bi-Centennial Conference, Philadelphia, 1940. Google Scholar2. Kern RA: Perennial allergic rhinitis: the most important respiratory allergy, Med. Clin. N. Am. 31: 1375, 1947. CrossrefMedlineGoogle Scholar3. Rackemann FM: Clinical allergy: asthma and hay fever, 1931, The Macmillan Company, New York. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pennsylvania*Read at the 32nd Annual Session of the American College of Physicians, St. Louis, Missouri, April 10, 1951.From the Division of Medicine, Temple University Hospital and Medical School. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySensitivity to hair dyesHormoneHormone 1 August 1951Volume 35, Issue 2Page: 315-322KeywordsAllergic diseasesAllergy and immunologyElderlyHospital medicine ePublished: 1 December 2008 Issue Published: 1 August 1951 PDF downloadLoading ...
The presence of the FRA12E/SMRT fragile site in the genome of prostate cancer patients is a predictor of metastatic development
Authors: Lionel Coignet, Christiane Houde, Jean Dolce, Brian Bundy, Mary Nesline, Christine Ambrosone, William McLaughlin, Donald Trump
Journal: Clinical Cancer Research (2006)

A60   Background: The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) gene that maps at chromosome 12q24 is a transcriptional co-repressor. Based on previous experiments in our Laboratory, we determined that prostate cancer cell lines and samples from prostate cancer patients with advanced disease have altered SMRT expression. We mapped a fragile site (FRA12E) within the SMRT gene. We hypothesized that patients with metastatic CaP have a higher incidence of FRA12E in their genome.Material and Methods: Blood samples were collected from 14 healthy men, 14 prostate cancer patients with no evidence of disease >5 years from diagnosis, and 14 men with metastatic CaP. Each sample was set in culture in the presence of aphidicoline (an inducer of fragile sites); chromosomes were harvested and fixed using classical cytogenetic techniques. SMRT-specific BAC clones were used in fluorescence in-situ hybridization (FISH) experiments using the patient9s metaphase chromosomes. Images were collected, scored, and analyzed for a disrupted FISH signal indicative of FRA12E presence. Clinical data were also recorded.Results: The results of this pilot study showed that 1/14 healthy individual was carrier of the FRA12E fragile site, none of the patients with no evidence of disease >5 years from their primary diagnostic were carrier of the fragile site whereas all the patients with spread disease studied were carrier.Discussion: This pilot study examines the incidence of FRA12E in the genome of prostate cancer patients and suggests that the presence of FRA12E may be a useful predictor for the development of metastatic disease. Larger studies are underway to validate this potentially powerful metastatic predictor.
ELISA in Diagnosis of Respiratory Allergy
Authors: A. C. Negrini, C. Troise, S. Voltolini
Journal: Allergy (1985)

An enzyme‐linked immunosorbent assay (ELISA), employing beta‐galactosidase conjugated anti‐IgE, was used for the determination of specific IgE antibodies to common inhalant allergens ( Dermatophagoides pt. and f. , Parietaria and four grass pollens) in serum samples from 82 adult patients with asthma and/or rhinitis. A total of 194 analysis were carried out and the results were compared with those of skin tests and RAST. The correlation coefficient ( r ) between ELISA and RAST results was high ( r = 0.95); the correlation between skin tests and ELISA ( r = 0.93) was greater than that between skin tests and RAST ( r = 0.90). No significant differences were found among the allergens used. We conclude that the version of ELISA used develops an overall good correlation with skin tests and RAST and seems to provide a satisfactory alternative to RAST for allergy diagnosis.
Regulation of Growth and Spacing of Gland Elements in the Mammary Fat Pad of the C3H Mouse&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: L. J. Faulkin, K. B. Deome
Journal: JNCI Journal of the National Cancer Institute (1960)

By means of the fat-pad transplant technique, competing systems of mammary-gland elements were established in the gland-free (cleared) and intact fat pads of C3H female mice. These experiments demonstrated the presence of a growth-regulating system within the intact mammary gland which determines both the spacing of the parenchymal elements and the extent of mammary-gland growth. This growth-regulating system was shown to be effective between normal gland elements, between normal gland elements and hyperactive outgrowth, between hyperactive outgrowths, and, to a limited extent, between normal ductal elements and tumors. The ability to override this growth-regulating system appears to be the principal characteristic of neoplastic tissue.
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
Authors: Salim Yusuf, Shamir R Mehta, Changchun Xie, Rashid J Ahmed, Denis Xavier, Prem Pais, Jun Zhu, Lisheng Liu
Journal: JAMA (2005)

ContextAlthough reperfusion therapy, aspirin, β-blockers, and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with acute myocardial infarction (MI), mortality and morbidity remain high. No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI.ObjectiveTo evaluate the effects of reviparin, a low-molecular-weight heparin, when initiated early and given for 7 days in addition to usual therapy on the primary composite outcome of death, myocardial reinfarction, or strokes at 7 and 30 days.Design, Setting, and PatientsA randomized, double-blind, placebo-controlled trial (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation [CREATE]) of 15 570 patients with ST-segment elevation or new left bundle-branch block, presenting within 12 hours of symptom onset at 341 hospitals in India and China from July 2001 through July 2004.InterventionReviparin or placebo subcutaneously twice daily for 7 days.Main Outcome MeasurePrimary composite outcome of death, myocardial reinfarction, or stroke at 7 and 30 days.ResultsThe primary composite outcome was significantly reduced from 854 (11.0%) of 7790 patients in the placebo group to 745 (9.6%) of 7780 in the reviparin group (hazard ratio [HR], 0.87; 95% CI, 0.79-0.96; P = .005). These benefits persisted at 30 days (1056 [13.6%] vs 921 [11.8%] patients; HR, 0.87; 95% CI, 0.79-0.95; P = .001) with significant reductions in 30-day mortality (877 [11.3%] vs 766 [9.8%]; HR, 0.87; 95% CI, 0.79-0.96; P = .005) and reinfarction (199 [2.6%] vs 154 [2.0%]; HR, 0.77; 95% CI, 0.62-0.95; P = .01), and no significant differences in strokes (64 [0.8%] vs 80 [1.0%]; P = .19). Reviparin treatment was significantly better when it was initiated very early after symptom onset at 7 days (<2 hours: HR, 0.70; 95% CI, 0.52-0.96; P = .03; 30/1000 events prevented; 2 to <4 hours: HR, 0.81; 95% CI, 0.67-0.98; P = .03; 21/1000 events prevented; 4 to <8 hours: HR, 0.85; 95% CI, 0.73-0.99; P = .05; 16/1000 events prevented; and ≥8 hours: HR, 1.06; 95% CI, 0.86-1.30; P = .58; P = .04 for trend). There was an increase in life-threatening bleeding at 7 days with reviparin and placebo (17 [0.2%] vs 7 [0.1%], respectively; P = .07), but the absolute excess was small (1 more per 1000) vs reductions in the primary outcome (18 fewer per 1000) or mortality (15 fewer per 1000).ConclusionsIn patients with acute ST-segment elevation or new left bundle-branch block MI, reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There is a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.
Prostate cancer cells induce osteoclastogenesis and bone resorption through RANKL-independent interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) production
Authors: Yi Lu, Zhong Cai, Guozhi Xiao, Zhi Yao, Judy L. Anderson, David G. Roodman, Jian Zhang
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

3972 

Prostate cancer (CaP) commonly metastasizes to bone resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlined, possibly prerequisite, osteoclastic activities at the bone metastatic sites. We have previously demonstrated that blocking receptor activator of NFκB ligand (RANKL) partially prevent the establishment of CaP in bone and diminishes the progression of CaP growth in the skeleton in murine models. However, RANKL in the serum from CaP patients or from the bone marrow of tumor sites in animal models or in the cell lines used in those studies was at very low level. These findings strongly suggest that soluble factors other than RANKL may mediate the tumor-induced osteclast activity. To identify these factors we first used a human cytokine antibody array (174 cytokines) to measure cytokine protein expression in conditioned medium (CM) collected from CaP cells LNCaP and C4-2B (the derivative from LNCaP but with bone metastastatic characteristics). We found that both cells produced significantly high amount of several cytokines such as IL-8 and MCP-1, but not IL-6, IL-11, TNFα, MIP-1α, and RANTES. Furthermore, IGFBP-2 and MMP-9 were found significantly higher in C4-2B CM than LNCaP CM. (4.4-fold for IGFBP-2 and 3.1-fold for MMP-9). These results were confirmed by using ELISA. Finally, murine osteoclast precursor RAW264.7, cells or human bone marrow-derived monocytes were cultured with LNCaP CM (10%). Within 24 hours, LNCaP-CM induced multinucleated TRAP positive osteoclast formation from RAW264.7 cells while the soluble RANKL (50ng/ml) required 96 hours to form mature osteoclasts. Recombinant human IL-8 (10ng/ml), but not MCP-1 (10ng/ml), directly stimulated Raw 264.7 differentiation into mature osteoclast and bone resorption on dentin slices within 6 days of culture in the absence of RANKL. LNCaP-CM-induced osteoclast formation and bone resorption from RAW264.7 cells and human bone marrow-derived monocytes (HBMC) were dose-dependently inhibited by adding anti-IL-8 neutralizing antibody and further synergistically inhibited with addition of MCP-1 antibody in HBMC. In summary, we have identified IL-8 and MCP-1 that produced by CaP cells directly induce osteoclastogenesis and bone resorption in vitro. Together with recent report that serum IL-8 level is elevated in men with CaP and bone metastases and MCP-1 as a key mediator involved in the recruitment of monocytes/macrophages in inflamed bone, this study may provide a targeting strategy for the treatment of CaP skeletal metastasis.
The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts
Authors: Marta Chesi, Elena Nardini, Robert S.C. Lim, Kerrington D. Smith, W. Michael Kuehl, P. Leif Bergsagel
Journal: Blood (1998)
The Alzheimer Sonnets
Authors: Ronald Pies
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TREATMENT OF ATTACKS OF SINUS TACHYCARDIA WITH PROSTIGMIN
Authors: Samuel Waldman, Samuel N. Moskowitz
Journal: Annals of Internal Medicine (1944)

Article1 May 1944THE TREATMENT OF ATTACKS OF SINUS TACHYCARDIA WITH PROSTIGMINSAMUEL WALDMAN, M.D., SAMUEL N. MOSKOWITZ, M.D.SAMUEL WALDMAN, M.D., SAMUEL N. MOSKOWITZ, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-20-5-793 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSinus tachycardia, or simple tachycardia as it is otherwise known, is defined by Herrmann1as "a sustained increase in the heart rate beyond the normal limits for the individual." Usually a rate of 100 beats per minute in a person over the age of 18 is evidence enough to justify a diagnosis of sinus tachycardia. It must be remembered that such criteria are not valid in childhood when the cardiac rate is normally more rapid. Therefore, the age of a patient is an important factor in the estimation of a normal heart rate. The condition is common, is usually of...Bibliography1. HERRMANN G: Disturbances of the heartbeat, in STROUD, W. D.: The diagnosis and treatment of cardiovascular disease, 1940, F. A. Davis Co., Philadelphia. Google Scholar2. WHITE PD: Heart disease, Ed. 2, 1937, Macmillan Co., New York. Google Scholar3. CABOT RC: Physical diagnosis, Ed. 9, 1938, William Wood Co., Baltimore. Google Scholar4. WALDMANMOSKOWITZ SSN: The effect of prostigmin on supraventricular tachycardias, Med. Rec., 1941, cliii, 134. Google Scholar5. AESCHLIMANNREINERT JAM: Pharmacological action of some analogues of physostigmine, Jr. Pharmacol. and Exper. Therap., 1931, xliii, 413. Google Scholar6. CARMICHAELFRASERMCKELVEYWILKIE EAFRDDP: Therapeutic action of prostigmin, Lancet, 1934, i, 942. CrossrefGoogle Scholar7. PELNER L: Prostigmin in paroxysmal tachycardia, Med. Rec., 1941, cliii, 209. Google Scholar8. BATTROSEGURALANARI ARGA: El prostigmin en el tratamiento de las taquicardias paroxisticas supraventriculares, Medicina, 1941, i, 4. Google Scholar9. BATTRO A: Personal Communication. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, New York*Received for publication December 9, 1942. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byModification of sinus node function by epicardial laser irradiation in dogs.Chronic Nonparoxysmal Sinus Tachycardia in Otherwise Healthy PersonsROBERT A. BAUERNFEIND, M.D., FERNANDO AMAT-Y-LEON, M.D., RAMESH C. DHINGRA, M.D., RICHARD KEHOE, M.D., CHRISTOPHER WYNDHAM, M.D., KENNETH M. ROSEN, M.D.Measures Used in the Prevention and Treatment of Cardiac ArrhythmiasParoxysmal tachycardia in infants 1 May 1944Volume 20, Issue 5Page: 793-805KeywordsHeart rateTachycardia ePublished: 1 December 2008 Issue Published: 1 May 1944 PDF downloadLoading ...
A valuable lesson: The doctor is on your side
Authors: T. Wells
Journal: BMJ (2000)

ality trait model of motivation prevalent in much of clinical literature, which does place this sort of responsibility on patients, can negatively affect engagement with rehabilitation. 20 21 Implications for further researchFurther research into the determinants of motivation is required.Ethnographic research into how patients are treated by rehabilitation professionals on the basis of labels such as "motivated" and "unmotivated," and the effects this might have on motivation, seems warranted.Research into how patients themselves categorise motivation might also be useful.All such research might help in maintaining motivation among rehabilitation patients, a task often taken to be "the most important, yet the most difficult part of the work of the therapeutic professions." 22 We thank the professionals on the stroke unit, the family members, and most of all the patients who agreed to be interviewed.We also thank Dr Ajay Bhalla.
Abstract 2701: Antitumor effects of peptide Rb4 derived from proteolipid protein 2 (PLP2) in a syngeneic murine melanoma model
Authors: Vera S C Maia, Rodrigo Berzaghi, Denise C. Arruda, Pollyana M S Melo, Luiz R. Travassos
Journal: Cancer Research (2014)

Abstract Peptides have increasingly being investigated as drug candidates for treatment of pathologies ranging from Alzheimer`s disease to cancer. Literature shows that over expression of proteolipid protein 2 (PLP2) was associated with metastasis of B16F10 melanoma. Authors showed later that knock-down of PLP2 inhibited growth and metastasis of melanoma cells. The present work aimed at studying the antitumor activity of peptide Rb4 derived from protein PLP2. Peptide Rb4, tested as synthetic peptide on B16F10-Nex2 cells showed antitumor effects in vitro and in vivo. Rb4 induces a remarkable F-actin depolymerization, and also antagonizes thapsigargin blockade of calcium channels on the endoplasmic reticulum (ER). Such effects on actin dynamics and calcium flow cause apoptosis in murine melanoma B16F10-Nex2, and reduce the viability of several human cancer cell lines. Chromatin condensation, DNA fragmentation, caspase 9 and caspase 3 activation are compatible with tumor cell apoptosis. Early effects of the peptide were cell rounding and aggregation, followed by substrate detachment. In vivo, peptide Rb4 reduced metastatic activity of B16F10-Nex2 cells and delayed the subcutaneous growth of murine melanoma in the syngeneic model. The protective effect of Rb4 observed in the metastatic melanoma model was not, however, observed in immunodeficient mice. Peptide Rb4 induces the expression of two DAMPs (damage-associated molecular patterns), HMGB1 and calreticulin in B16F10-Nex2. Apart from a direct adjuvant effect of Rb4 on dendritic cells (DCs), the expression of DAMPs by tumor cells may also contribute to DCs activation thus explaining the protective effect of the peptide in vivo against B16F10-Nex2 melanoma. In conclusion, we suggest that peptide Rb4 is a promising compound to be developed as an anticancer drug. Supported by FAPESP grant 2010/51423-0 and the Brazilian National Research Council (CNPq). Citation Format: Vera S C Maia, Rodrigo Berzaghi, Denise C. Arruda, Pollyana M S Melo, Luiz R. Travassos. Antitumor effects of peptide Rb4 derived from proteolipid protein 2 (PLP2) in a syngeneic murine melanoma model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2701. doi:10.1158/1538-7445.AM2014-2701
Abstract 18279: Roles of Aldosterone, Mineralocorticoid Inhibition and G6PD Activity in Microvascular Endothelial Dysfunction in African Americans with Hypertension
Authors: Tisha M Suboc, Kodlipet Dharmashankar, Jingli Wang, Rong Ying, Michael E Widlansky
Journal: Circulation (2014)

Systemic aldosterone levels are more strongly correlated with blood pressure in African Americans (AAs) than Caucasians, and aldosterone impairs vascular endothelial function in part by impairing G6PD activity in animal studies. The impact of physiological levels of aldosterone or acute mineralocorticoid blockade on microvascular endothelial function and G6PD activity in arterioles from AAs with and without hypertension (HTN) remains unclear. 37 AAs subjects (13 with HTN, 24 controls) underwent non-invasive studies of microvascular endothelial function using digital pulse arterial tonometry (DPAT). Systemic G6PD activity, renin, and aldosterone levels were measured. Subcutaneous gluteal arterioles were harvested from 15 of these subjects. Arteriolar endothelium-dependent vasodilation was testing using increasing doses of acetylcholine (Ach) and measured by videomicroscopy. Vessels were tested with or without 1 hour of pre-treatment with aldosterone (20 ng/dL) or spironolactone (10 μM). Arteriolar G6PD act...